Literature DB >> 17825925

Tumour-derived microvesicles modulate biological activity of human monocytes.

Monika Baj-Krzyworzeka1, Rafał Szatanek, Kazimierz Weglarczyk, Jarosław Baran, Marek Zembala.   

Abstract

Tumour cells are shedding membrane fragments (tumour-derived microvesicles, TMV) that may interact with cells of immune system. Our previous observations indicated that TMV carry several surface determinants and mRNA of tumour cells and transfer some of them to monocytes. This study determined the effect of TMV on biological activity of human monocytes as the precursors of tumour infiltrating macrophages (TIM). It was found that TMV activated monocytes as shown by an increased HLA-DR expression, induced production of ROI (reactive oxygen intermediates) and of tumour necrosis factor (TNF), interleukin (IL)-10, IL-12p40 accumulation of mRNA and their secretion. Induction of TNF synthesis was CD44 dependent as blocking of CD44 on monocytes abolished its secretion. TMV-treated monocytes showed an increased antitumour activity as judged by enhanced cytotoxicity/cytostasis against tumour cells in vitro. Taken together, these results indicate that TMV significantly modulate biological activity of monocytes and thus mimic the effect of tumour cells on them. This may suggest that tumour cells interact with TIM not only via direct contact, soluble factors, but also TMV.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17825925     DOI: 10.1016/j.imlet.2007.07.014

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  43 in total

1.  Interleukin-17 and prostaglandin E2 are involved in formation of an M2 macrophage-dominant microenvironment in lung cancer.

Authors:  Lunxu Liu; Dongxia Ge; Lin Ma; Jiandong Mei; Sen Liu; Qiuyang Zhang; Fuqiang Ren; Hu Liao; Qiang Pu; Tao Wang; Zongbing You
Journal:  J Thorac Oncol       Date:  2012-07       Impact factor: 15.609

Review 2.  Membrane vesicles as conveyors of immune responses.

Authors:  Clotilde Théry; Matias Ostrowski; Elodie Segura
Journal:  Nat Rev Immunol       Date:  2009-06-05       Impact factor: 53.106

3.  Detection of microvesicle miRNA expression in ALL subtypes and analysis of their functional roles.

Authors:  Wen-Ying Li; Xiao-Mei Chen; Wei Xiong; Dong-Mei Guo; Li Lu; Hui-Yu Li
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2014-10-16

Review 4.  Extracellular vesicles: biology and emerging therapeutic opportunities.

Authors:  Samir EL Andaloussi; Imre Mäger; Xandra O Breakefield; Matthew J A Wood
Journal:  Nat Rev Drug Discov       Date:  2013-04-15       Impact factor: 84.694

Review 5.  Extracellular RNA mediates and marks cancer progression.

Authors:  Jasmina S Redzic; Leonora Balaj; Kristan E van der Vos; Xandra O Breakefield
Journal:  Semin Cancer Biol       Date:  2014-04-28       Impact factor: 15.707

6.  Autocrine activation of human monocyte/macrophages by monocyte-derived microparticles and modulation by PPARγ ligands.

Authors:  C Bardelli; A Amoruso; D Federici Canova; Lg Fresu; P Balbo; T Neri; A Celi; S Brunelleschi
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

7.  A new role for microRNAs, as ligands of Toll-like receptors.

Authors:  Muller Fabbri; Alessio Paone; Federica Calore; Roberta Galli; Carlo M Croce
Journal:  RNA Biol       Date:  2013-01-07       Impact factor: 4.652

8.  Activation of macrophages by P2X7-induced microvesicles from myeloid cells is mediated by phospholipids and is partially dependent on TLR4.

Authors:  L Michael Thomas; Russell D Salter
Journal:  J Immunol       Date:  2010-08-13       Impact factor: 5.422

Review 9.  Membrane microparticles: shedding new light into cancer cell communication.

Authors:  Paloma Silva de Souza; Roberta Soares Faccion; Paula Sabbo Bernardo; Raquel Ciuvalschi Maia
Journal:  J Cancer Res Clin Oncol       Date:  2015-08-19       Impact factor: 4.553

10.  The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time.

Authors:  Junliang Ma; Lunxu Liu; Guowei Che; Nanbin Yu; Fuqiang Dai; Zongbing You
Journal:  BMC Cancer       Date:  2010-03-25       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.